Our finding that PRL3-zumab effectively suppressed PRL3+ orthotopic liver tumors presents a solution to a long-standing challenge in medical treatment of HCC, whose pathophysiologic complexity is often exacerbated by underlying functional liver insufficiency. The gene discussed is PTP4A3; the disease is hepatocellular carcinoma.